NCT03617328View on ClinicalTrials.gov

Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

November 13, 2018

Primary Completion Date

January 19, 2024

Study Completion Date

January 19, 2024

Conditions
Melanoma
Interventions
BIOLOGICAL

6MHP

6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides

DRUG

Montanide ISA-51

Montanide ISA-51 (Incomplete Freund's Adjuvant), local adjuvant

DRUG

polyICLC

polyICLC, local adjuvant

DRUG

CDX-1127

CDX-1127, anti-CD27 monoclonal antibody

Trial Locations (2)

22908

University of Virginia, Charlottesville

23284

Virginia Commonwealth University, Richmond

Sponsors

Collaborators (1)

Celldex Therapeutics
All Listed Sponsors
collaborator

Celldex Therapeutics

INDUSTRY

lead

Craig L Slingluff, Jr

OTHER

NCT03617328 - Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma | Biotech Hunter | Biotech Hunter